晚发型依非韦伦神经毒性综合征(LENS)的药物遗传学研究
研究前瞻性纳入15例接受依非韦伦方案抗逆转录病毒治疗并出现晚发型依非韦伦神经毒性综合征(LENS)的成人HIV阳性者,采用药物遗传学与药代动力学分析。15例均为CYP2B6慢代谢型,依非韦伦血浆浓度中位数50.5(47.0-65.4)µg/mL,远高于治疗范围上限。作者认为LENS与CYP2B6慢代谢基因型相关,异烟肼和低体重是重要促发因素。
要点
- 15例LENS患者全部为CYP2B6慢代谢型,其中6例兼有CYP2A6杂合基因型。
- 依非韦伦血浆浓度中位数50.5(47.0-65.4)µg/mL,为治疗范围上限的12倍以上。
- 13例同时使用异烟肼,15例均为NAT2慢或中间乙酰化基因型。
核心结论
- 作者认为本队列提供了明确证据,表明LENS与CYP2B6慢代谢基因型相关。
- 依非韦伦血浆浓度中位数为50.5(47.0-65.4)µg/mL,高于既定治疗范围上限12倍以上。
- 异烟肼与低体重是LENS发生的重要促发因素。
研究设计与样本
- 前瞻性纳入接受以依非韦伦为基础抗逆转录病毒治疗的成人HIV阳性者,均表现为LENS。
- 选取与依非韦伦血浆浓度升高相关的CYP2B6(rs3745274、rs28399499、rs4803419)和CYP2A6(rs28399433)基因多态性判定慢代谢型比例。
- 采用液相色谱-串联质谱法进行药代动力学分析。
- 共纳入15例参与者。
主要发现
- 15例中13例为非洲黑人,13例为女性;体重中位数49.9kg,依非韦伦使用时间中位数2.2年。
- 15例均成功基因分型为CYP2B6慢代谢型,其中6例兼有CYP2A6杂合基因型。
- 13例正在使用CYP2A6酶抑制剂异烟肼,15例均为NAT2慢或中间乙酰化基因型。
- 依非韦伦血浆浓度为50.5(47.0-65.4)µg/mL,明显升高。
- 8-羟基依非韦伦浓度为0.10(0.07-0.15)µg/mL,明显降低。
关键数值与推荐
- LENS表现为共济失调和/或脑病,伴依非韦伦血浆浓度超治疗范围(>4 µg/mL)。
- 依非韦伦主要经细胞色素P450 2B6(CYP2B6)代谢,CYP2A6为辅助通路。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The late-onset efavirenz neurotoxicity syndrome (LENS) presents as ataxia and/or encephalopathy with supratherapeutic efavirenz plasma concentrations (>4 µg/mL). Efavirenz is primarily metabolized by cytochrome P450 2B6 (CYP2B6), with CYP2A6 as an accessory pathway. We hypothesized that participants with LENS would predominantly be CYP2B6 slow metabolizers. The aim of our study was to determine the frequency of CYP2B6 slow metabolizers in participants with LENS. METHODS: Adult HIV-positive participants on efavirenz-based antiretroviral therapy presenting with LENS were prospectively enrolled. Genetic polymorphisms known to be associated with increased efavirenz plasma concentrations in CYP2B6 (rs3745274, rs28399499, rs4803419) and CYP2A6 (rs28399433) were selected and used to determine proportions of slow metabolizers. Pharmacokinetic analyses were performed using liquid chromatography-tandem mass spectrometry. Median (IQR) plasma efavirenz and 8-hydroxyefavirenz were described. RESULTS: Fifteen participants were enrolled. Thirteen (13/15) were Black-African and 13 were female. Median weight was 49.9kg with a median duration on efavirenz of 2.2 years. All 15 participants were successfully genotyped as slow CYP2B6 metabolizers, with 6 participants additionally having CYP2A6 heterozygous genotype. Thirteen were receiving the CYP2A6 enzyme inhibitor isoniazid, and all 15 were genotypic NAT2 slow or intermediate acetylators. Efavirenz plasma concentration was markedly increased at 50.5 (47.0-65.4) µg/mL; 8-hydroxyefavirenz concentration was markedly decreased at 0.10 (0.07-0.15) µg/mL. CONCLUSIONS: Our cohort provides definitive evidence that LENS is associated with the CYP2B6 slow metabolizer genotype, with a median efavirenz plasma concentration >12-fold higher than the defined upper limit of the therapeutic range. Isoniazid and low body weight are important contributors to LENS development.
引用
- van Rensburg R, Nightingale S, Brey N, et al. Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS). Clin Infect Dis. 2022. PMID: 34882770. doi:10.1093/cid/ciab961
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。